Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Affymetrix's Stock Is Soaring Today

By George Budwell - Jan 11, 2016 at 11:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares jump after the company's board approves a buyout offer from Thermo Fisher Scientific.

Image source: Madprime.

WhatAffymetrix (AFFX.DL), a leader in genomics analysis, gained nearly 50% today on exceptionally high volume following the news that Thermo Fisher Scientific's (TMO 0.04%) proposal to acquire the company for $14.00 per share, or $1.3 billion, in an all-cash deal, was approved by the boards of both companies. This price represents a 52% premium compared to where Affymetrix's shares were trading prior to the deal being announced last Friday. 

So what: This transaction should help to grow Thermo's footprint in the red-hot area of biogenetic analysis. In particular, Thermo's management noted that this deal significantly expands its antibody portfolio in the fast-growing flow cytometry market.

Now what: Thermo has made a huge effort by taking a rather aggressive approach to M&A in the past few years to become a top dog in the burgeoning biosciences field that serves the biopharmaceutical industry. So, this deal seems to fit quite nicely with the company's overarching goal.

The bigger issue to understand, though, is that Thermo is clearly targeting high-growth markets such as biomarker detection and protein engineering based on its recent acquisition history. Fortunately for investors, this is probably a smart move due to the growing importance of biologically based therapies and personalized medicine in the industry. Put simply, Thermo now appears to be well-positioned to take advantage of this powerful trend in biopharma, potentially making it a great stock to buy and hold for the long haul. 

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Thermo Fisher Scientific Inc. Stock Quote
Thermo Fisher Scientific Inc.
TMO
$590.26 (0.04%) $0.26
Affymetrix Inc. Stock Quote
Affymetrix Inc.
AFFX.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.